Knowledge of Pregnant Women Concerning Pertussis, Vaccination Against Pertussis and Cocooning Strategy

Launched by UNIVERSITÉ DE REIMS CHAMPAGNE-ARDENNE · Oct 27, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how much pregnant women know about whooping cough (pertussis), the importance of getting vaccinated against it, and a strategy called “cocooning” that helps protect newborns. Since 2022, it has been recommended in France for pregnant women to receive a pertussis vaccine between 20 to 36 weeks of pregnancy. This vaccine is important because it helps pass protective antibodies from the mother to the baby, which is crucial since whooping cough can be very serious for newborns.

To participate in this trial, women must be pregnant for between 20 to 41 weeks, be expecting their first child (first-time mothers), and be over 18 years old. They also need to agree to take part in the study. Unfortunately, women who have had previous children, are under legal guardianship, or do not wish to participate cannot join. If eligible, participants can expect to contribute to important research that could help improve awareness and vaccination strategies for protecting newborns against whooping cough.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Pregnant between 20 and 41 weeks of amenorrhea
• • Primiparous
• • aged more than 18
• • Agreed to participate in the study
• Exclusion Criteria:
• • Multiparous
• • Protected by law (guardianship, guardianship, safeguarding of justice)
• • Not agreed to participate in this study